Related Experiment Videos
Immunosuppressive therapy
1Department of Surgery, University of Texas Health Science Center, Houston 77030.
Current Opinion in Immunology
|October 1, 1992
Summary
New immunosuppressive agents and antibody technologies aim to improve organ transplant outcomes by overcoming the limitations of Cyclosporin A. Research focuses on broadening the therapeutic window for better patient results.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Medicine
Background:
- Cyclosporin A improves transplant outcomes but has a narrow therapeutic window and significant limitations.
- Alternative immunosuppressants like Rapamycin and Brequinar show synergistic effects.
- Existing agents like FK-506 and monoclonal antibodies have limitations including side effects and immunogenicity.
Purpose of the Study:
- To review current and emerging immunosuppressive strategies for organ transplantation.
- To discuss the challenges and potential solutions for broadening the therapeutic window of immunosuppressive drugs.
- To highlight advancements in monoclonal antibody technology for transplantation.
Main Methods:
- Review of existing literature on immunosuppressive agents in organ transplantation.
- Analysis of pharmacokinetic profiling and drug formulation strategies.
- Examination of monoclonal antibody technology and 'humanization' techniques.
Main Results:
- New agents (Rapamycin, Brequinar) and formulations offer potential to broaden the therapeutic window.
- FK-506, while potent, does not necessarily offer a broader therapeutic window than Cyclosporin A.
- Advancements in monoclonal antibodies aim to reduce side effects and improve efficacy in transplantation.
Conclusions:
- A range of novel immunosuppressive agents and antibody-based therapies are emerging for organ transplantation.
- Overcoming the narrow therapeutic window of current drugs is a key challenge.
- Development of clinical trial methodologies is crucial for evaluating these new agents effectively.